CYC 065

Drug Profile

CYC 065

Alternative Names: CYC-065

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Antineoplastics; Purines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 5 inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; MCL1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours
  • Preclinical Chronic lymphocytic leukaemia; Neuroblastoma

Most Recent Events

  • 18 Apr 2018 Preclinical trials in Chronic lymphocytic leukaemia in USA (unspecified route)
  • 16 Apr 2018 Efficacy and pharmacokinetics data from a phase I trial in Solid tumours released by Cyclacel Pharmaceuticals
  • 28 Mar 2018 Cyclacel Pharmaceuticals plans an investigator sponsored clinical trial for Leukaemia (In adults, In infants, In children, In adolescents), in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top